Business
Amgen Drug Hits Its Goals in Sjögren’s Disease, a Common Autoimmune Illness With No Approved Treatment
Dazodalibep met its main targets in a Phase 3 trial for Sjögren’s — the autoimmune disease that dries out eyes and mouths for up to 4 million Americans and has never had an FDA-approved therapy.